The association between maternal urinary phthalate metabolites concentrations and pregnancy induced hypertension: Results from the EDEN Mother-Child Cohort.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 02 06 2021
revised: 25 08 2021
accepted: 30 08 2021
pubmed: 6 9 2021
medline: 31 12 2021
entrez: 5 9 2021
Statut: ppublish

Résumé

Studies have suggested that exposure to endocrine disruptors such as phthalates that are widely used in our daily life (food wrapping, cosmetics, toys, medical devices, polyvinyl chloride flooring, and building materials) might be related to raised blood pressure and increased risk of cardiovascular diseases. Phthalates might induce a pro-inflammatory response and increased oxidative stress and may be a cause of pregnancy induced hypertension. We evaluated the association between maternal exposure to phthalates during pregnancy and pregnancy induced hypertension. 604 pregnant women were included and eleven phthalate metabolites were quantified in spot maternal urine samples collected between the 23rd and 28th week of gestation in a French EDEN mother-child cohort. The associations were assessed by applying multiple logistic regression analysis. Twenty nine (4,8%) mothers developed pregnancy induced hypertension. Two low molecular weight phthalate metabolites: Monoethyl phthalate (MEP) and Mono-n‑butyl phthalate (MBP) were positively associated with pregnancy induced hypertension in crude (Odds Ratio: 1.43, 95% Confidence Interval: 1.04-1.96, p-value = 0.02 and 1.48, 1.10-2.01, p-value =0.01) and in adjusted (1.47, 1.01-2.14, p-value = 0.04 and 1.66, 1.11-2.47, p-value = 0.01) models respectively. Our data suggest that prenatal exposure to some phthalates, including MEP and MBP, might play a role in pregnancy induced hypertension.

Sections du résumé

BACKGROUND BACKGROUND
Studies have suggested that exposure to endocrine disruptors such as phthalates that are widely used in our daily life (food wrapping, cosmetics, toys, medical devices, polyvinyl chloride flooring, and building materials) might be related to raised blood pressure and increased risk of cardiovascular diseases. Phthalates might induce a pro-inflammatory response and increased oxidative stress and may be a cause of pregnancy induced hypertension.
METHODS METHODS
We evaluated the association between maternal exposure to phthalates during pregnancy and pregnancy induced hypertension. 604 pregnant women were included and eleven phthalate metabolites were quantified in spot maternal urine samples collected between the 23rd and 28th week of gestation in a French EDEN mother-child cohort. The associations were assessed by applying multiple logistic regression analysis.
RESULTS RESULTS
Twenty nine (4,8%) mothers developed pregnancy induced hypertension. Two low molecular weight phthalate metabolites: Monoethyl phthalate (MEP) and Mono-n‑butyl phthalate (MBP) were positively associated with pregnancy induced hypertension in crude (Odds Ratio: 1.43, 95% Confidence Interval: 1.04-1.96, p-value = 0.02 and 1.48, 1.10-2.01, p-value =0.01) and in adjusted (1.47, 1.01-2.14, p-value = 0.04 and 1.66, 1.11-2.47, p-value = 0.01) models respectively.
CONCLUSION CONCLUSIONS
Our data suggest that prenatal exposure to some phthalates, including MEP and MBP, might play a role in pregnancy induced hypertension.

Identifiants

pubmed: 34482002
pii: S2468-7847(21)00153-7
doi: 10.1016/j.jogoh.2021.102216
pii:
doi:

Substances chimiques

Phthalic Acids 0
phthalic acid 6O7F7IX66E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102216

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None

Auteurs

Munawar Hussain Soomro (MH)

Sorbonne Université and INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, 27 rue Chaligny 75571 Paris CEDEX 12, France; L'Institut Desbrest d'Épidémiologie et de Santé Publique (IDESP), INSERM & University of Montpellier, IURC, 641, Avenue du Doyen Gaston Giraud, 34093, Montpellier, France; Department of Community Medicine, Chandka Medical College, SMBB Medical University, Larkana, Pakistan. Electronic address: munawar_soomro@hotmail.com.

Cara Nichole Maesano (CN)

Sorbonne Université and INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, 27 rue Chaligny 75571 Paris CEDEX 12, France.

Barbara Heude (B)

INSERM, UMR 1153 Epidemiology and Biostatistics Sorboone Paris Cite Center (CRESS), Early origin of the Child's Health and Development Team (ORCHAD), Paris, France; Paris Descartes University, Paris, France.

Carl-Gustaf Bornehag (CG)

Department of Health Sciences, Karlstad University, Karlstad, Sweden; Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York City, United States.

Isabella Annesi-Maesano (I)

L'Institut Desbrest d'Épidémiologie et de Santé Publique (IDESP), INSERM & University of Montpellier, IURC, 641, Avenue du Doyen Gaston Giraud, 34093, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH